GlycoMimetics Forges Ahead With Uproleselan In AML After Phase III Failure

 
• By Alaric DeArment

The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing, with an unusually long OS result in the control arm.

• Source: Shutterstock

More from Clinical Trials

More from R&D